论文部分内容阅读
最近,已确定胃H~+/K~+-ATP酶是胃的质子泵,胃内酸的产生是由它承担的。这些研究导致将H~+/K~+-ATP酶作为抗分泌剂的新靶的进行研究。奥美拉唑就是此类中进入临床研究的第一个药物,并于1988年上市。新的作用机制已引起了日益增加的注意,据1988年的《药品数据年报》报道,应用质子泵抑制剂的病人数会超过服用H_2-受体拮抗剂的病人数。日本武田药厂的科学家合成了一系列的苯并咪唑取代物,并试验了它们对H~+/K~+-
Recently, it has been determined that gastric H ~ + / K ~ + -ATPase is a proton pump in the stomach, and stomach acid is responsible for its production. These studies led to the study of H ~ + / K ~ + -ATPase as a new target of antisecretory agents. Omeprazole is the first of its kind to enter clinical trials and went on the market in 1988. The new mechanism of action has drawn increasing attention, as reported in the 1988 Annual Drug Data Bulletin, the number of patients using proton pump inhibitors exceeds the number of patients taking H 2 -receptor antagonists. Scientists from Takeda Pharmaceuticals of Japan synthesized a series of benzimidazole substitutes and tested their effect on H ~ + / K ~ + -